首页 > 最新文献

Pigment Cell & Melanoma Research最新文献

英文 中文
The Proposed Categorization of Vitiligo Lesions on the Hands 建议对手部白癜风病变进行分类
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-07-10 DOI: 10.1111/pcmr.70039
Kazunori Yokoi, Yosuke Ishitsuka, Kanae Kusao, Jing Wang, Haruna Kawashima, Narumi Jikihara, Seitaro Nakagawa, Eiji Kiyohara, Noriko Arase, Manabu Fujimoto, Atsushi Tanemura

Vitiligo is a common depigmentation disorder characterized by patchy white macules. It has been reported that vitiligo lesions, particularly in exposed areas, such as the face and hands, cause severe psychological distress. Although the classification and outcome of facial vitiligo have been proposed, clinical analyses featuring hand vitiligo are very limited, irrespective of its severe psychological impact. In this study, we investigated hand lesions in nonsegmental vitiligo patients and found that the distribution of hand vitiligo was symmetric, whereas the dominant hand was more frequently affected. Moreover, our clustering analysis newly classified hand vitiligo lesions into four distinct subtypes (n = 140): focal/scattered (46.4%), distal digit (31.4%), universal (12.9%), and proximal digit (9.2%) and their clinical characteristics. The focal/scattered type is the most common subtype and exhibits a distinctive prevalence in pediatric cases. The distal digit type was suggested to be associated with smoking or the Koebner phenomenon. The universal type is a distinct subtype, with onset in older age and a poor response to treatment. The proximal digit type is the rarest subtype, with onset at a young age. In conclusion, these findings deepen our understanding of the heterogeneity of hand vitiligo and support the development of personalized treatment strategies.

白癜风是一种常见的以斑点状白色斑点为特征的色素沉着障碍。据报道,白癜风病变,特别是在暴露区域,如面部和手部,会造成严重的心理困扰。尽管已经提出了面部白癜风的分类和预后,但对手部白癜风的临床分析非常有限,无论其严重的心理影响如何。在本研究中,我们调查了非节段性白癜风患者的手部病变,发现手部白癜风的分布是对称的,而优势手更容易受到影响。此外,我们的聚类分析新将手部白癜风病变分为四个不同的亚型(n = 140):局灶/分散(46.4%),远端(31.4%),普遍(12.9%)和近端(9.2%)及其临床特征。局灶/分散型是最常见的亚型,在儿科病例中表现出独特的患病率。远端指型被认为与吸烟或Koebner现象有关。通用型是一种独特的亚型,发病年龄较大,对治疗反应较差。近端指型是最罕见的亚型,发病年龄小。总之,这些发现加深了我们对手部白癜风异质性的理解,并支持个性化治疗策略的发展。
{"title":"The Proposed Categorization of Vitiligo Lesions on the Hands","authors":"Kazunori Yokoi,&nbsp;Yosuke Ishitsuka,&nbsp;Kanae Kusao,&nbsp;Jing Wang,&nbsp;Haruna Kawashima,&nbsp;Narumi Jikihara,&nbsp;Seitaro Nakagawa,&nbsp;Eiji Kiyohara,&nbsp;Noriko Arase,&nbsp;Manabu Fujimoto,&nbsp;Atsushi Tanemura","doi":"10.1111/pcmr.70039","DOIUrl":"https://doi.org/10.1111/pcmr.70039","url":null,"abstract":"<p>Vitiligo is a common depigmentation disorder characterized by patchy white macules. It has been reported that vitiligo lesions, particularly in exposed areas, such as the face and hands, cause severe psychological distress. Although the classification and outcome of facial vitiligo have been proposed, clinical analyses featuring hand vitiligo are very limited, irrespective of its severe psychological impact. In this study, we investigated hand lesions in nonsegmental vitiligo patients and found that the distribution of hand vitiligo was symmetric, whereas the dominant hand was more frequently affected. Moreover, our clustering analysis newly classified hand vitiligo lesions into four distinct subtypes (<i>n</i> = 140): focal/scattered (46.4%), distal digit (31.4%), universal (12.9%), and proximal digit (9.2%) and their clinical characteristics. The focal/scattered type is the most common subtype and exhibits a distinctive prevalence in pediatric cases. The distal digit type was suggested to be associated with smoking or the Koebner phenomenon. The universal type is a distinct subtype, with onset in older age and a poor response to treatment. The proximal digit type is the rarest subtype, with onset at a young age. In conclusion, these findings deepen our understanding of the heterogeneity of hand vitiligo and support the development of personalized treatment strategies.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144598211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PRMT6 Inhibits Malignant Progression of Melanoma by Antagonizing Trimethylation of Histone H3K4 to Downregulate ALDH1A1 Levels PRMT6通过拮抗组蛋白H3K4三甲基化下调ALDH1A1水平抑制黑色素瘤恶性进展
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-07-09 DOI: 10.1111/pcmr.70034
Man Cai, Liangyu Wang, Miao Sun, Meixi Liu, Yingchun Liu

Protein arginine methyltransferase 6 (PRMT6), a member of the PRMT family capable of self-arginine methylation, is down-regulated in melanoma, but the specific mechanism is still unclear. Our work demonstrated that PRMT6 overexpression significantly inhibited the ability of melanoma cells to proliferate, tumorigenicity, migration, and invasion, whereas PRMT6 knockdown rescued these malignant behaviors of melanoma cells. Mechanistically, we identified aldehyde dehydrogenase 1A1 (ALDH1A1) as a critical downstream target of PRMT6. PRMT6 knockdown up-regulated ALDH1A1 expression, exacerbating melanoma aggressiveness in vitro. Further investigations revealed that PRMT6 modulates ALDH1A1 expression by catalyzing asymmetric dimethylation of histone H3 at arginine 2 (H3R2me2a) and antagonizing the enrichment of histone H3 lysine 4 trimethylation (H3K4me3) at the ALDH1A1 promoter. In addition, dual-luciferase experiments showed that the transcription factor KLF4 may bind to the −1800 ~ +45 sequence of PRMT6, thereby negatively regulating PRMT6 expression in melanoma. Our findings underscore the tumor-suppressive role of PRMT6 in melanoma pathogenesis, highlighting its potential as a novel therapeutic target, particularly for metastatic melanoma.

蛋白精氨酸甲基转移酶6 (Protein arginine methyltransferase 6, PRMT6)是PRMT家族中的一员,能够进行自精氨酸甲基化,在黑色素瘤中下调,但具体机制尚不清楚。我们的研究表明,PRMT6过表达可显著抑制黑色素瘤细胞的增殖、致瘤性、迁移和侵袭能力,而PRMT6敲低可挽救黑色素瘤细胞的这些恶性行为。在机制上,我们发现醛脱氢酶1A1 (ALDH1A1)是PRMT6的一个关键下游靶点。PRMT6敲低上调ALDH1A1表达,在体外加剧黑色素瘤侵袭性。进一步的研究表明,PRMT6通过催化组蛋白H3在精氨酸2位点的不对称二甲基化(H3R2me2a)和拮抗组蛋白H3赖氨酸4三甲基化(H3K4me3)在ALDH1A1启动子位点的富集来调节ALDH1A1的表达。此外,双荧光素酶实验表明,转录因子KLF4可能结合PRMT6的−1800 ~ +45序列,从而负向调节PRMT6在黑色素瘤中的表达。我们的研究结果强调了PRMT6在黑色素瘤发病机制中的肿瘤抑制作用,强调了它作为一种新的治疗靶点的潜力,特别是对于转移性黑色素瘤。
{"title":"PRMT6 Inhibits Malignant Progression of Melanoma by Antagonizing Trimethylation of Histone H3K4 to Downregulate ALDH1A1 Levels","authors":"Man Cai,&nbsp;Liangyu Wang,&nbsp;Miao Sun,&nbsp;Meixi Liu,&nbsp;Yingchun Liu","doi":"10.1111/pcmr.70034","DOIUrl":"https://doi.org/10.1111/pcmr.70034","url":null,"abstract":"<div>\u0000 \u0000 <p>Protein arginine methyltransferase 6 (PRMT6), a member of the PRMT family capable of self-arginine methylation, is down-regulated in melanoma, but the specific mechanism is still unclear. Our work demonstrated that PRMT6 overexpression significantly inhibited the ability of melanoma cells to proliferate, tumorigenicity, migration, and invasion, whereas PRMT6 knockdown rescued these malignant behaviors of melanoma cells. Mechanistically, we identified aldehyde dehydrogenase 1A1 (ALDH1A1) as a critical downstream target of PRMT6. PRMT6 knockdown up-regulated ALDH1A1 expression, exacerbating melanoma aggressiveness in vitro. Further investigations revealed that PRMT6 modulates ALDH1A1 expression by catalyzing asymmetric dimethylation of histone H3 at arginine 2 (H3R2me2a) and antagonizing the enrichment of histone H3 lysine 4 trimethylation (H3K4me3) at the ALDH1A1 promoter. In addition, dual-luciferase experiments showed that the transcription factor KLF4 may bind to the −1800 ~ +45 sequence of PRMT6, thereby negatively regulating PRMT6 expression in melanoma. Our findings underscore the tumor-suppressive role of PRMT6 in melanoma pathogenesis, highlighting its potential as a novel therapeutic target, particularly for metastatic melanoma.</p>\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma YAP上调有助于葡萄膜黑色素瘤对BET抑制剂的获得性耐药性
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-07-07 DOI: 10.1111/pcmr.70036
Yan-ling Zhou, Xiao-lian Liu, Si-Si Huang, Gui-ming Zhang, Xuan-yu Jin, Liang Chen, Le Yu, Yi-lei Li

BET inhibitors have the potential to treat malignant tumors via the epigenetic modification mechanism. Although BET inhibitors show promise as anticancer agents for uveal melanoma (UM), the emergence of acquired resistance significantly limits their clinical efficacy. We developed isogenic OTX015-resistant UM cell models (OMM2.3R and OMM2.5R) via exposure to escalating OTX015 concentrations (0.04–0.5 μM over 6 months). These resistant cells demonstrated reduced sensitivity to OTX015-induced cytotoxicity. Moreover, the migratory ability of resistant cells was less affected by OTX015 compared to parental cells. Transcriptome analysis revealed an upregulation of YAP-activated genes in resistant cells. Notably, OTX015-resistant cells retained sensitivity to YAP inhibition via shRNA or pharmacological inhibitors. This study establishes YAP activation as a novel compensatory mechanism driving BET inhibitor resistance in UM. These findings position YAP inhibition as a potential therapeutic target to overcome BET inhibitor resistance, with clinical translational potential for resistant UM patients.

BET抑制剂具有通过表观遗传修饰机制治疗恶性肿瘤的潜力。尽管BET抑制剂有望作为葡萄膜黑色素瘤(UM)的抗癌药物,但获得性耐药的出现显著限制了其临床疗效。通过暴露于不断升高的OTX015浓度(0.04-0.5 μM / 6个月),我们开发了耐OTX015的等基因UM细胞模型(OMM2.3R和OMM2.5R)。这些耐药细胞表现出对otx015诱导的细胞毒性的敏感性降低。此外,与亲本细胞相比,OTX015对抗性细胞的迁移能力影响较小。转录组分析显示耐药细胞中yap活化基因上调。值得注意的是,otx015耐药细胞通过shRNA或药物抑制剂保留了对YAP抑制的敏感性。本研究确立了YAP激活作为一种新的代偿机制驱动BET抑制剂在UM中的抗性。这些发现表明YAP抑制是克服BET抑制剂耐药的潜在治疗靶点,对耐药UM患者具有临床转化潜力。
{"title":"YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma","authors":"Yan-ling Zhou,&nbsp;Xiao-lian Liu,&nbsp;Si-Si Huang,&nbsp;Gui-ming Zhang,&nbsp;Xuan-yu Jin,&nbsp;Liang Chen,&nbsp;Le Yu,&nbsp;Yi-lei Li","doi":"10.1111/pcmr.70036","DOIUrl":"https://doi.org/10.1111/pcmr.70036","url":null,"abstract":"<div>\u0000 \u0000 <p>BET inhibitors have the potential to treat malignant tumors via the epigenetic modification mechanism. Although BET inhibitors show promise as anticancer agents for uveal melanoma (UM), the emergence of acquired resistance significantly limits their clinical efficacy. We developed isogenic OTX015-resistant UM cell models (OMM2.3R and OMM2.5R) via exposure to escalating OTX015 concentrations (0.04–0.5 μM over 6 months). These resistant cells demonstrated reduced sensitivity to OTX015-induced cytotoxicity. Moreover, the migratory ability of resistant cells was less affected by OTX015 compared to parental cells. Transcriptome analysis revealed an upregulation of YAP-activated genes in resistant cells. Notably, OTX015-resistant cells retained sensitivity to YAP inhibition via shRNA or pharmacological inhibitors. This study establishes YAP activation as a novel compensatory mechanism driving BET inhibitor resistance in UM. These findings position YAP inhibition as a potential therapeutic target to overcome BET inhibitor resistance, with clinical translational potential for resistant UM patients.</p>\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidermotropic Metastatic Melanoma Presenting as Eruptive Primary Melanomas 表皮性转移性黑色素瘤表现为发疹性原发性黑色素瘤
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-07-04 DOI: 10.1111/pcmr.70037
Jennifer Strong, Mitchell J. Winkie, Patrick Hallaert, Scott B. Whitecar, Elaine S. Keung, Daniel Neelon, Karen G. Zeman, Michele M. Gage, William C. Schaffenburg, Meagan M. Simpson, Isaac Brownell

We report on the use of molecular profiling to diagnose epidermotropic metastatic melanoma (EMM) in a patient who presented with eruptive primary melanomas. On histopathology, the patient's metastatic lesions resembled superficial spreading melanomas and were indistinguishable from independent primary melanomas. The patient's presumed primary melanoma was a stage IIIB nodular melanoma. Despite treatment with adjuvant nivolumab, the patient continued to form new superficial spreading melanomas. Due to suspicion for EMM, commercial panel sequencing was performed on tissue from four tumors. Comparison of reported somatic variants revealed a mutational profile that was conserved across all four lesions, establishing a diagnosis of stage IV EMM. Considering the progressive disease on immunotherapy, treatment was transitioned to encorafenib plus binimetinib, resulting in regression of existing lesions and cessation of new skin lesion formation. Aside from micrometastatic sentinel lymph node deposits from the presumed primary melanoma, the patient had no evidence of non-cutaneous metastases. EMM should be considered as a diagnosis for multiple superficial spreading melanomas arising synchronously or in rapid succession. As EMM and primary melanomas are often histopathologically indistinguishable, next generation sequencing is a valuable tool to confirm clonality and provide a definitive diagnosis.

我们报告使用分子谱诊断表皮性转移性黑色素瘤(EMM)的患者谁提出了爆发原发性黑色素瘤。在组织病理学上,患者的转移性病变类似于表面扩散的黑色素瘤,与独立的原发性黑色素瘤难以区分。患者的原发性黑色素瘤为IIIB期结节性黑色素瘤。尽管辅助治疗纳武单抗,患者继续形成新的浅表扩散黑色素瘤。由于怀疑EMM,对四个肿瘤组织进行了商业小组测序。比较报告的体细胞变异揭示了在所有四个病变中保守的突变谱,建立了IV期EMM的诊断。考虑到免疫治疗的进展性疾病,将治疗过渡到依可非尼加比尼美替尼,导致现有病变消退,停止新的皮肤病变形成。除了推测为原发性黑色素瘤的微转移前哨淋巴结沉积外,患者无非皮肤转移的证据。EMM应被视为同时或快速连续出现的多个浅表扩散黑色素瘤的诊断。由于EMM和原发性黑色素瘤通常在组织病理学上难以区分,下一代测序是确认克隆性和提供明确诊断的有价值的工具。
{"title":"Epidermotropic Metastatic Melanoma Presenting as Eruptive Primary Melanomas","authors":"Jennifer Strong,&nbsp;Mitchell J. Winkie,&nbsp;Patrick Hallaert,&nbsp;Scott B. Whitecar,&nbsp;Elaine S. Keung,&nbsp;Daniel Neelon,&nbsp;Karen G. Zeman,&nbsp;Michele M. Gage,&nbsp;William C. Schaffenburg,&nbsp;Meagan M. Simpson,&nbsp;Isaac Brownell","doi":"10.1111/pcmr.70037","DOIUrl":"https://doi.org/10.1111/pcmr.70037","url":null,"abstract":"<div>\u0000 \u0000 <p>We report on the use of molecular profiling to diagnose epidermotropic metastatic melanoma (EMM) in a patient who presented with eruptive primary melanomas. On histopathology, the patient's metastatic lesions resembled superficial spreading melanomas and were indistinguishable from independent primary melanomas. The patient's presumed primary melanoma was a stage IIIB nodular melanoma. Despite treatment with adjuvant nivolumab, the patient continued to form new superficial spreading melanomas. Due to suspicion for EMM, commercial panel sequencing was performed on tissue from four tumors. Comparison of reported somatic variants revealed a mutational profile that was conserved across all four lesions, establishing a diagnosis of stage IV EMM. Considering the progressive disease on immunotherapy, treatment was transitioned to encorafenib plus binimetinib, resulting in regression of existing lesions and cessation of new skin lesion formation. Aside from micrometastatic sentinel lymph node deposits from the presumed primary melanoma, the patient had no evidence of non-cutaneous metastases. EMM should be considered as a diagnosis for multiple superficial spreading melanomas arising synchronously or in rapid succession. As EMM and primary melanomas are often histopathologically indistinguishable, next generation sequencing is a valuable tool to confirm clonality and provide a definitive diagnosis.</p>\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation 具有异质繁殖潜能的黑色素瘤细胞黑色素含量的前瞻性分离
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-30 DOI: 10.1111/pcmr.70011
Clare Fedele, Gamze Kuser-Abali, Ralph Rossi, Peinan Zhao, Jason Li, Malaka Ameratunga, Pacman Szeto, YouFang Zhang, Miles Andrews, Mark Shackleton

Intra-tumoral heterogeneity poses a major challenge to treating and managing cancer patients. A characteristic feature of melanoma is its composition of cancer cells with typically heterogeneous content of melanin pigment, the production of which is a hallmark of normal melanocytic differentiation but of poorly understood consequence in melanoma cells, as prospective assessment of pigment heterogeneity in melanoma cells has been experimentally challenging. Here, we describe a novel flow cytometric method for high purity separation of viable melanoma cells based on their melanin content, exploiting the light scattering properties of melanin. By fluorescence-activated cell sorting, we show that cells with low-pigment content (LPCs) in melanoma cell lines and patient tumors are usually far more abundant than high-pigment cells (HPCs) and have substantially increased potentials for colony formation in vitro and tumor formation in vivo. In RNAseq analysis, HPCs showed P53 activation and perturbed cell cycling, whereas LPCs displayed upregulation of MYC-associated transcription and activated ribosome biogenesis. In proof-of-concept studies, the latter was targeted by topoisomerase 2 beta targeting with CX-5461, which induced senescent HPC phenotypes and irreversible loss of clonogenic activity. These data indicate an ‘inverted pyramid’ hierarchical model of melanoma cell propagation wherein abundant LPCs frequently renew their own malignant potential to propagate disease but also infrequently generate HPCs that spontaneously lose this ability in a manner that might be exploited as an anti-melanoma strategy.

肿瘤内异质性是治疗和管理癌症患者的主要挑战。黑色素瘤的一个特征是其癌细胞的组成具有典型的黑色素色素异质性,黑色素色素的产生是正常黑色素细胞分化的标志,但对黑色素瘤细胞的后果知之甚少,因为黑色素瘤细胞色素异质性的前瞻性评估在实验上具有挑战性。在这里,我们描述了一种新的流式细胞术方法,用于基于黑色素含量的活黑色素瘤细胞的高纯度分离,利用黑色素的光散射特性。通过荧光激活的细胞分选,我们发现黑色素瘤细胞系和患者肿瘤中低色素含量的细胞(LPCs)通常比高色素含量的细胞(HPCs)丰富得多,并且在体外集落形成和体内肿瘤形成的潜力大大增加。在RNAseq分析中,HPCs显示P53激活和细胞周期紊乱,而LPCs显示myc相关转录上调和激活核糖体生物发生。在概念验证研究中,CX-5461靶向拓扑异构酶2 β,诱导衰老的HPC表型和不可逆的克隆生成活性丧失。这些数据表明了黑色素瘤细胞繁殖的“倒金字塔”分层模型,其中大量的LPCs经常更新其自身的恶性潜能以传播疾病,但也很少产生自发丧失这种能力的HPCs,这种能力可能被用作抗黑色素瘤策略。
{"title":"Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation","authors":"Clare Fedele,&nbsp;Gamze Kuser-Abali,&nbsp;Ralph Rossi,&nbsp;Peinan Zhao,&nbsp;Jason Li,&nbsp;Malaka Ameratunga,&nbsp;Pacman Szeto,&nbsp;YouFang Zhang,&nbsp;Miles Andrews,&nbsp;Mark Shackleton","doi":"10.1111/pcmr.70011","DOIUrl":"https://doi.org/10.1111/pcmr.70011","url":null,"abstract":"<p>Intra-tumoral heterogeneity poses a major challenge to treating and managing cancer patients. A characteristic feature of melanoma is its composition of cancer cells with typically heterogeneous content of melanin pigment, the production of which is a hallmark of normal melanocytic differentiation but of poorly understood consequence in melanoma cells, as prospective assessment of pigment heterogeneity in melanoma cells has been experimentally challenging. Here, we describe a novel flow cytometric method for high purity separation of viable melanoma cells based on their melanin content, exploiting the light scattering properties of melanin. By fluorescence-activated cell sorting, we show that cells with low-pigment content (LPCs) in melanoma cell lines and patient tumors are usually far more abundant than high-pigment cells (HPCs) and have substantially increased potentials for colony formation in vitro and tumor formation in vivo. In RNAseq analysis, HPCs showed P53 activation and perturbed cell cycling, whereas LPCs displayed upregulation of MYC-associated transcription and activated ribosome biogenesis. In proof-of-concept studies, the latter was targeted by topoisomerase 2 beta targeting with CX-5461, which induced senescent HPC phenotypes and irreversible loss of clonogenic activity. These data indicate an ‘inverted pyramid’ hierarchical model of melanoma cell propagation wherein abundant LPCs frequently renew their own malignant potential to propagate disease but also infrequently generate HPCs that spontaneously lose this ability in a manner that might be exploited as an anti-melanoma strategy.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response 免疫疗法Rechallenge对大多数Ipilimumab + Nivolumab初始应答后晚期进展的患者有效
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-18 DOI: 10.1111/pcmr.70023
Ethan Trim, Anita Giobbie-Hurder, Tamara A. Sussman, David Liu, Megan Insco, Rizwan Haq, F. Stephen Hodi, Patrick A. Ott, Elizabeth I. Buchbinder

Clinical benefit achieved with ipilimumab + nivolumab combination therapy is typically long lasting. However, late progression, after therapy completion, does occur in a subset of patients. At the time of late progression, immunotherapy options include anti-PD-1 monotherapy, anti-PD-1/LAG-3, repeat anti-PD-1/CTLA-4 therapy, or TIL therapy, but the efficacy of these approaches is unknown. To investigate, we evaluated 230 patients with advanced melanoma who received treatment with ipilimumab + nivolumab at Dana-Farber Cancer Institute between 2015 and 2022 as first-line treatment. Of these, 111 had an initial response of stable disease (SD) or better for 6 months or longer. Of the 111 deriving clinical benefit, 19 had late progression, 14 while off therapy. Ten of the 14 patients who had late progression off therapy were rechallenged with immune checkpoint inhibition (ICB), either as monotherapy or in combination. Eight out of those 10 patients had clinical benefit of SD or better upon ICB rechallenge. The two who did not benefit from rechallenge had mucosal melanoma (3 patients had mucosal, 7 had cutaneous). The data indicate that clinical benefit upon rechallenge with ICB can be achieved in the majority of patients, specifically those with the cutaneous subtype, although responses are mostly SD and are relatively short lived.

伊匹单抗+纳武单抗联合治疗的临床获益通常是持久的。然而,治疗完成后的晚期进展确实发生在一部分患者中。在晚期进展时,免疫治疗选择包括抗pd -1单药治疗、抗pd -1/LAG-3、重复抗pd -1/CTLA-4治疗或TIL治疗,但这些方法的疗效尚不清楚。为了进行研究,我们评估了2015年至2022年间在丹娜-法伯癌症研究所接受伊匹单抗+纳武单抗治疗的230例晚期黑色素瘤患者。其中,111例患者在6个月或更长时间内病情稳定(SD)或更好。在111例临床获益患者中,19例进展较晚,14例在停药期间。14例晚期停止治疗的患者中有10例再次接受免疫检查点抑制(ICB),无论是单一治疗还是联合治疗。10例患者中有8例在ICB再挑战后获得SD或更好的临床获益。2例未从再挑战中获益的患者有粘膜黑色素瘤(3例为粘膜,7例为皮肤)。数据表明,大多数患者,特别是皮肤亚型患者,在再次接受ICB治疗后可以获得临床获益,尽管反应大多为SD且持续时间相对较短。
{"title":"Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response","authors":"Ethan Trim,&nbsp;Anita Giobbie-Hurder,&nbsp;Tamara A. Sussman,&nbsp;David Liu,&nbsp;Megan Insco,&nbsp;Rizwan Haq,&nbsp;F. Stephen Hodi,&nbsp;Patrick A. Ott,&nbsp;Elizabeth I. Buchbinder","doi":"10.1111/pcmr.70023","DOIUrl":"https://doi.org/10.1111/pcmr.70023","url":null,"abstract":"<div>\u0000 \u0000 <p>Clinical benefit achieved with ipilimumab + nivolumab combination therapy is typically long lasting. However, late progression, after therapy completion, does occur in a subset of patients. At the time of late progression, immunotherapy options include anti-PD-1 monotherapy, anti-PD-1/LAG-3, repeat anti-PD-1/CTLA-4 therapy, or TIL therapy, but the efficacy of these approaches is unknown. To investigate, we evaluated 230 patients with advanced melanoma who received treatment with ipilimumab + nivolumab at Dana-Farber Cancer Institute between 2015 and 2022 as first-line treatment. Of these, 111 had an initial response of stable disease (SD) or better for 6 months or longer. Of the 111 deriving clinical benefit, 19 had late progression, 14 while off therapy. Ten of the 14 patients who had late progression off therapy were rechallenged with immune checkpoint inhibition (ICB), either as monotherapy or in combination. Eight out of those 10 patients had clinical benefit of SD or better upon ICB rechallenge. The two who did not benefit from rechallenge had mucosal melanoma (3 patients had mucosal, 7 had cutaneous). The data indicate that clinical benefit upon rechallenge with ICB can be achieved in the majority of patients, specifically those with the cutaneous subtype, although responses are mostly SD and are relatively short lived.</p>\u0000 </div>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disruption of mc1r Disturbs Skin Pigmentation in Xenopus tropicalis mc1r的破坏扰乱了热带非洲爪蟾的皮肤色素沉着
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-16 DOI: 10.1111/pcmr.70033
Lanxin Li, Jixuan Huang, Yonglong Chen, Rensen Ran

The melanocortin 1 receptor (MC1R) is well-established as a pivotal regulator of pigmentation in various species. Despite a wealth of research focused on mammals and fish, the role of Mc1r in amphibians has remained largely unexplored. This study was designed to elucidate the contribution of Mc1r in Xenopus tropicalis. Our results reveal that targeted ablation of mc1r in Xenopus tropicalis led to a significant reduction in dorsal skin pigmentation, while simultaneously accelerating the onset of melanophore pigmentation in the ventral region. This dual effect resulted in a perturbation of the canonical countershading pattern. Additionally, knockout of mc1r disrupted the expression of multiple genes primarily associated with pigmentation. Collectively, these findings underscore the critical role of MC1R in the regulation of pigmentation and the development of countershading in amphibians, contributing to the growing body of literature on the evolution and function of MC1R across vertebrate species.

黑素皮质素1受体(MC1R)在许多物种中被认为是色素沉着的关键调节因子。尽管对哺乳动物和鱼类进行了大量的研究,但Mc1r在两栖动物中的作用在很大程度上仍未被探索。本研究旨在阐明Mc1r在热带非洲爪蟾中的作用。我们的研究结果表明,靶向消融热带非洲爪蟾mc1r导致背侧皮肤色素沉着显著减少,同时加速了腹侧区域黑色素沉着的发生。这种双重效应导致了规范反遮阳模式的扰动。此外,敲除mc1r破坏了主要与色素沉着相关的多个基因的表达。总的来说,这些发现强调了MC1R在两栖动物色素沉着调控和反遮光发育中的关键作用,有助于越来越多的关于MC1R在脊椎动物物种中的进化和功能的文献。
{"title":"Disruption of mc1r Disturbs Skin Pigmentation in Xenopus tropicalis","authors":"Lanxin Li,&nbsp;Jixuan Huang,&nbsp;Yonglong Chen,&nbsp;Rensen Ran","doi":"10.1111/pcmr.70033","DOIUrl":"https://doi.org/10.1111/pcmr.70033","url":null,"abstract":"<p>The melanocortin 1 receptor (MC1R) is well-established as a pivotal regulator of pigmentation in various species. Despite a wealth of research focused on mammals and fish, the role of Mc1r in amphibians has remained largely unexplored. This study was designed to elucidate the contribution of Mc1r in <i>Xenopus tropicalis</i>. Our results reveal that targeted ablation of <i>mc1r</i> in <i>Xenopus tropicalis</i> led to a significant reduction in dorsal skin pigmentation, while simultaneously accelerating the onset of melanophore pigmentation in the ventral region. This dual effect resulted in a perturbation of the canonical countershading pattern. Additionally, knockout of <i>mc1r</i> disrupted the expression of multiple genes primarily associated with pigmentation. Collectively, these findings underscore the critical role of MC1R in the regulation of pigmentation and the development of countershading in amphibians, contributing to the growing body of literature on the evolution and function of MC1R across vertebrate species.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144299576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SASH1 Mutations and Hereditary Disorders of Pigmentation: Review of Literature SASH1突变与色素沉着遗传性疾病:文献综述
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-13 DOI: 10.1111/pcmr.70032
Anuradha Bishnoi, Aarushi Arunima, Keshavamurthy Vinay, Muthu Sendhil Kumaran, Davinder Parsad

Dyschromatosis universalis hereditaria (DUH) is a rare genodermatosis characterized by asymptomatic hyper- and hypopigmented macules appearing in infancy and persisting for life. Although mutations in ABCB6 account for many DUH cases, recently, the SAM and SH3 domain-containing 1 (SASH1) gene has emerged as a key player in DUH. Additionally, SASH1 mutations have been associated with the pure-lentiginous phenotype of familial pigmentation. In this review of literature, we found 22 different SASH1 mutations, most inherited in an autosomal dominant manner. These variants cause distinct phenotypes, including DUH, lentiginosis, and rarely, an autosomal recessive syndromic form with alopecia, palmoplantar keratoderma, and increased risk of malignancies. Functional studies have revealed that SASH1 acts as both a tumor suppressor and a pro-melanogenic factor. It modulates key pathways such as p53–POMC–α-MSH–MC1R–MITF and Gαs-SASH1–IQGAP1–E-cadherin pathways, affecting melanosome production, transport, and melanocyte migration. This unique dual role of SASH1 highlights its importance in melanocyte homeostasis and UV-induced pigmentation. Understanding the role of SASH1 in regulating pigmentation can help foster novel therapeutic approaches for these genodermatoses and related pigmentary anomalies, ultimately improving patient care and outcomes.

普遍遗传性色素异常症(DUH)是一种罕见的遗传性皮肤病,其特征是无症状的高色素和低色素斑,出现在婴儿期并持续一生。虽然ABCB6突变导致了许多DUH病例,但最近,SAM和SH3结构域1 (SASH1)基因在DUH中发挥了关键作用。此外,SASH1突变与家族性色素沉着的纯色素性表型有关。在这篇文献综述中,我们发现了22种不同的SASH1突变,大多数以常染色体显性方式遗传。这些变异引起不同的表型,包括DUH、黄斑病,以及罕见的常染色体隐性综合征形式,如脱发、掌跖角化病和恶性肿瘤的风险增加。功能研究表明SASH1同时作为肿瘤抑制因子和促黑色素生成因子。它调节p53-POMC -α-MSH-MC1R-MITF和g - s- sash1 - iqgap1 - e -cadherin等关键通路,影响黑素小体的产生、运输和黑素细胞的迁移。这种独特的双重作用突出了SASH1在黑素细胞稳态和紫外线诱导的色素沉着中的重要性。了解SASH1在调节色素沉着中的作用有助于为这些遗传性皮肤病和相关色素异常提供新的治疗方法,最终改善患者的护理和预后。
{"title":"SASH1 Mutations and Hereditary Disorders of Pigmentation: Review of Literature","authors":"Anuradha Bishnoi,&nbsp;Aarushi Arunima,&nbsp;Keshavamurthy Vinay,&nbsp;Muthu Sendhil Kumaran,&nbsp;Davinder Parsad","doi":"10.1111/pcmr.70032","DOIUrl":"https://doi.org/10.1111/pcmr.70032","url":null,"abstract":"<p>Dyschromatosis universalis hereditaria (DUH) is a rare genodermatosis characterized by asymptomatic hyper- and hypopigmented macules appearing in infancy and persisting for life. Although mutations in ABCB6 account for many DUH cases, recently, the SAM and SH3 domain-containing 1 (SASH1) gene has emerged as a key player in DUH. Additionally, SASH1 mutations have been associated with the pure-lentiginous phenotype of familial pigmentation. In this review of literature, we found 22 different SASH1 mutations, most inherited in an autosomal dominant manner. These variants cause distinct phenotypes, including DUH, lentiginosis, and rarely, an autosomal recessive syndromic form with alopecia, palmoplantar keratoderma, and increased risk of malignancies. Functional studies have revealed that SASH1 acts as both a tumor suppressor and a pro-melanogenic factor. It modulates key pathways such as p53–POMC–α-MSH–MC1R–MITF and Gαs-SASH1–IQGAP1–E-cadherin pathways, affecting melanosome production, transport, and melanocyte migration. This unique dual role of SASH1 highlights its importance in melanocyte homeostasis and UV-induced pigmentation. Understanding the role of SASH1 in regulating pigmentation can help foster novel therapeutic approaches for these genodermatoses and related pigmentary anomalies, ultimately improving patient care and outcomes.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Neuro-Endocrinal Regulation in Vitiligo 白癜风的神经内分泌调节
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-02 DOI: 10.1111/pcmr.70029
Wei Liu, Wanlu Ma, Xiao Xue, Shanshan Li

Vitiligo is an acquired depigmentation disorder characterized by the loss of melanocytes. The specific etiology of vitiligo is not fully understood, but it is thought to result from a complex interplay of factors, including autoimmune responses, intrinsic melanocyte dysfunction, genetic susceptibility, oxidative stress, and neurogenic imbalances. The disfiguring nature of vitiligo significantly impacts the mental and physical health of patients, and psychological stress can further induce and exacerbate vitiligo. Recent research has underscored the potential mediating roles of the hypothalamic–pituitary–adrenal axis, hormones, and neuropeptides in the pathogenesis of vitiligo. Furthermore, individuals with vitiligo have been shown to have a notably higher prevalence of diabetes mellitus and metabolic syndrome compared to the general population. This evidence suggests that vitiligo is not merely a cosmetic issue confined to the skin but also a systemic disease with broader health implications. This review aims to explore the potential roles and mechanisms of neuroendocrine factors in the pathogenesis of vitiligo, shedding light on the multifaceted nature of this condition and its systemic associations.

白癜风是一种以黑色素细胞丧失为特征的获得性色素沉着障碍。白癜风的具体病因尚不完全清楚,但被认为是多种因素复杂相互作用的结果,包括自身免疫反应、内在黑素细胞功能障碍、遗传易感性、氧化应激和神经源性失衡。白癜风的毁容性显著影响患者的身心健康,心理应激可进一步诱发和加重白癜风。最近的研究强调了下丘脑-垂体-肾上腺轴、激素和神经肽在白癜风发病中的潜在介导作用。此外,与一般人群相比,白癜风患者患糖尿病和代谢综合征的患病率明显更高。这一证据表明,白癜风不仅仅是一个局限于皮肤的美容问题,而且是一种具有更广泛健康影响的全身性疾病。本文旨在探讨神经内分泌因子在白癜风发病中的潜在作用和机制,揭示白癜风的多面性及其系统性关联。
{"title":"The Neuro-Endocrinal Regulation in Vitiligo","authors":"Wei Liu,&nbsp;Wanlu Ma,&nbsp;Xiao Xue,&nbsp;Shanshan Li","doi":"10.1111/pcmr.70029","DOIUrl":"https://doi.org/10.1111/pcmr.70029","url":null,"abstract":"<p>Vitiligo is an acquired depigmentation disorder characterized by the loss of melanocytes. The specific etiology of vitiligo is not fully understood, but it is thought to result from a complex interplay of factors, including autoimmune responses, intrinsic melanocyte dysfunction, genetic susceptibility, oxidative stress, and neurogenic imbalances. The disfiguring nature of vitiligo significantly impacts the mental and physical health of patients, and psychological stress can further induce and exacerbate vitiligo. Recent research has underscored the potential mediating roles of the hypothalamic–pituitary–adrenal axis, hormones, and neuropeptides in the pathogenesis of vitiligo. Furthermore, individuals with vitiligo have been shown to have a notably higher prevalence of diabetes mellitus and metabolic syndrome compared to the general population. This evidence suggests that vitiligo is not merely a cosmetic issue confined to the skin but also a systemic disease with broader health implications. This review aims to explore the potential roles and mechanisms of neuroendocrine factors in the pathogenesis of vitiligo, shedding light on the multifaceted nature of this condition and its systemic associations.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma 转移性黑色素瘤患者循环肿瘤细胞的微流控表征和分析
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2025-06-02 DOI: 10.1111/pcmr.70030
Matthew C. Mannino, Shuang G. Zhao, Benjamin K. Gibbs, Jennifer L. Schehr, Isabella G. Fernandez, Diego A. Eyzaguirre, Alyssa M. Hintz, Stephanie J. Davis, Manushi N. Vatani, Jacob C. Caceres, Alexander Birbrair, Joshua M. Lang, Vincent T. Ma

Circulating tumor cells (CTCs) can provide non-invasive insight into how a cancer patient responds to therapy. Their role in disease monitoring of advanced melanoma patients treated with immune checkpoint inhibitors (ICI) is unknown. CTC protein expression of human leukocyte antigen class-I (HLA I) and programmed death ligand-1 (PD-L1) may give insight into how a patient's disease evolves over the course of treatment. In our study, we utilize microfluidic Exclusion-based Sample Preparation (ESP) technology to isolate and characterize CTCs from patients with advanced-stage melanoma. CTC samples from melanoma patients are collected, captured, and stained. A range of 2 to 35 CTCs is observed in a cohort of 16 samples from 10 advanced-stage melanoma patients treated with ICI therapy. Single-cell protein expression data is generated from image cytometry analysis and used to calculate mean HLA I and PD-L1 expression. Using our ESP capture approach, we successfully detect phenotypic and numerical heterogeneity in CTCs from melanoma patients. Our assay shows sufficient capture sensitivity and promising prognostic and predictive information, as we illustrate in our case example. A greater clinical sample size will be necessary to confirm the diagnostic sensitivity and specificity of the assay in predicting clinical outcomes for patients with advanced-stage melanoma.

循环肿瘤细胞(CTCs)可以提供非侵入性的洞察癌症患者对治疗的反应。它们在免疫检查点抑制剂(ICI)治疗的晚期黑色素瘤患者的疾病监测中的作用尚不清楚。人类白细胞抗原I类(HLA I)和程序性死亡配体-1 (PD-L1)的CTC蛋白表达可能有助于了解患者疾病在治疗过程中的演变。在我们的研究中,我们利用基于微流控排斥的样品制备(ESP)技术从晚期黑色素瘤患者中分离和表征ctc。收集、捕获黑色素瘤患者的CTC样本并进行染色。在接受ICI治疗的10例晚期黑色素瘤患者的16个样本队列中观察到2至35个ctc。单细胞蛋白表达数据由图像细胞术分析生成,用于计算HLA I和PD-L1的平均表达。使用我们的ESP捕获方法,我们成功地检测了黑色素瘤患者ctc的表型和数值异质性。我们的分析显示出足够的捕获灵敏度和有希望的预后和预测信息,正如我们在案例中所说明的那样。需要更大的临床样本量来确认该方法在预测晚期黑色素瘤患者临床结果方面的诊断敏感性和特异性。
{"title":"Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma","authors":"Matthew C. Mannino,&nbsp;Shuang G. Zhao,&nbsp;Benjamin K. Gibbs,&nbsp;Jennifer L. Schehr,&nbsp;Isabella G. Fernandez,&nbsp;Diego A. Eyzaguirre,&nbsp;Alyssa M. Hintz,&nbsp;Stephanie J. Davis,&nbsp;Manushi N. Vatani,&nbsp;Jacob C. Caceres,&nbsp;Alexander Birbrair,&nbsp;Joshua M. Lang,&nbsp;Vincent T. Ma","doi":"10.1111/pcmr.70030","DOIUrl":"https://doi.org/10.1111/pcmr.70030","url":null,"abstract":"<p>Circulating tumor cells (CTCs) can provide non-invasive insight into how a cancer patient responds to therapy. Their role in disease monitoring of advanced melanoma patients treated with immune checkpoint inhibitors (ICI) is unknown. CTC protein expression of human leukocyte antigen class-I (HLA I) and programmed death ligand-1 (PD-L1) may give insight into how a patient's disease evolves over the course of treatment. In our study, we utilize microfluidic Exclusion-based Sample Preparation (ESP) technology to isolate and characterize CTCs from patients with advanced-stage melanoma. CTC samples from melanoma patients are collected, captured, and stained. A range of 2 to 35 CTCs is observed in a cohort of 16 samples from 10 advanced-stage melanoma patients treated with ICI therapy. Single-cell protein expression data is generated from image cytometry analysis and used to calculate mean HLA I and PD-L1 expression. Using our ESP capture approach, we successfully detect phenotypic and numerical heterogeneity in CTCs from melanoma patients. Our assay shows sufficient capture sensitivity and promising prognostic and predictive information, as we illustrate in our case example. A greater clinical sample size will be necessary to confirm the diagnostic sensitivity and specificity of the assay in predicting clinical outcomes for patients with advanced-stage melanoma.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pigment Cell & Melanoma Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1